- How is breast cancer treated?
- Surgery for breast cancer
- Radiation therapy for breast cancer
- Chemotherapy for breast cancer
- Hormone therapy for breast cancer
- Targeted therapy for breast cancer
- Bone-directed therapy for breast cancer
- Clinical trials for breast cancer
- Complementary and alternative therapies for breast cancer
Hormone therapy for breast cancer
Cancers that have hormone receptors in the cells (are ER-positive or PR-positive) are called hormone receptor-positive. In those cancers, the female hormone estrogen promotes the growth of the cancer. Hormone therapy for breast cancer works by blocking the effects of estrogen or lowering estrogen levels.
It can be used to help reduce the risk of the cancer coming back after surgery. It is also helpful in treating advanced breast cancer.
Drugs used to block estrogen
Tamoxifen and toremifene (Fareston®): These drugs stop estrogen from telling cells to grow and divide.
In women with early-stage breast cancer that is hormone receptor-positive, taking tamoxifen every day lowers the chance of the cancer coming back. It is taken by mouth every day for at least 5 years after surgery. Tamoxifen is also used to treat hormone receptor-positive breast cancer that has spread.
This drug has side effects. The most common ones are tiredness, hot flashes, vaginal discharge, and mood swings. More serious side effects are rare and can include uterine cancer and blood clots in the leg or lung. Still, for almost all women with breast cancer, the benefits of tamoxifen far outweigh the risks.
Toremifene works like tamoxifen, but is not used as often and is only approved for patients with advanced breast cancer. The side effects of these drugs are similar.
Fulvestrant: Fulvestrant (Faslodex®) is a drug that blocks the estrogen receptor and then also makes it go away for a time. It is given as a shot once a month. Hot flashes, mild nausea, and tiredness are the major side effects. It can be used to treat women with advanced breast cancer after other hormone drugs stop working.
Drugs used to change hormone levels
Aromatase inhibitors (AIs): The ovaries make most of the body’s estrogen before menopause. After menopause, a small amount of estrogen is made in fat tissue. These drugs stop the fat tissue from making estrogen. They only lower estrogen levels if the ovaries aren’t working (like after menopause). In women who have gone through menopause, AIs are the main drugs used to reduce the chance of hormone receptor-positive breast cancer from coming back. They can be used instead of tamoxifen or after a couple of years of tamoxifen treatment. They are also used to treat advanced breast cancer. These drugs are taken daily as pills.
The most common side effect of AIs is muscle and/or joint pain. This sometimes gets better if the patient is switched to another AI. Because they remove estrogens from the body, AIs can cause bone thinning which can cause bones to break. If women can’t take AIs because of side effects, they are usually switched to tamoxifen to complete 5 years of hormone treatment.
Luteinizing hormone-releasing hormone (LHRH) analogs: The ovaries are the main source of estrogens in women who have not gone through menopause,. Drugs that shut down the ovaries lower estrogen levels. These drugs, called LHRH analogs, can be used to treat advanced hormone receptor-positive breast cancers on their own. They are more often used with other hormone therapy drugs to help them work better. They are given as injections, most often once a month. Side effects are the same as symptoms of menopause, such as hot flashes, night sweats, vaginal dryness, and mood swings.
Surgery to change hormone levels
Removing the ovaries: Surgery to remove the ovaries can be used instead of LHRH analogs to lower estrogen levels in women who have not gone through menopause.
Other types of hormone treatment
Some other drugs can be used to treat hormone receptor-positive breast cancer, but they are used rarely, if it all. They are discussed in our document, Breast Cancer.
Last Medical Review: 09/17/2013
Last Revised: 10/24/2013